Evidence Explorer · MS-N281 · Unsupported cancer-treatment claim · Appraised November 9, 2026
Methadone is a legitimate opioid for pain and opioid-use disorder, but human evidence does not establish it as an anticancer treatment. Public enthusiasm came largely from laboratory experiments and small uncontrolled safety series.
Evidence at a glance
- Population: small observational series of people with high-grade glioma receiving standard therapy plus D,L-methadone.
- Clinical evidence: no randomized trial has shown improved tumor response, progression-free survival or overall survival from methadone.
- Preclinical boundary: several experiments required concentrations that may not be safely achievable in people, and clinically relevant concentrations did not consistently radiosensitize glioblastoma cells.
- Evidence label: no established cancer-control efficacy; high-risk prescription opioid.
What was studied
A 27-person safety and tolerance report combined methadone with chemotherapy but lacked a randomized comparator and was not designed to establish an anticancer effect. Later observational case series have the same confounding problem.
A critical pharmacology review concluded that clinical evidence for a tumoricidal effect is missing and questioned whether proposed brain concentrations are achievable. Methadone can still be appropriate for carefully supervised cancer pain; that is a separate clinical goal.
What this evidence cannot establish
Pain relief, sedation or an uncontrolled survival observation cannot establish tumor control. Laboratory sensitization at high concentrations does not show that a tolerable dose improves outcomes with temozolomide or radiation.
Safety and practical context
Methadone carries boxed warnings for fatal respiratory depression, QT prolongation and dangerous interactions with benzodiazepines, alcohol, other sedatives and CYP-modifying drugs.
Accumulation and delayed toxicity make internet titration especially hazardous. Cancer-related organ dysfunction, electrolyte abnormalities and interacting antiemetics or targeted agents can increase arrhythmia or overdose risk.
Questions for the care team
- Is methadone being proposed for pain control or as an unproven anticancer drug?
- Have the ECG, electrolytes, opioid history and interacting medicines been reviewed?
- Who will prescribe, titrate and provide overdose-safety planning?
Sources and identifiers
- Critical review of methadone repurposing for glioblastoma — PMID 32560384
- Uncontrolled glioma safety and tolerance series — PMID 28314286
- Observational opioid-naive glioma case series — PMID 32060760
- Current US methadone prescribing information
Funding and conflicts: Funding and conflicts were not fully re-extracted for the observational reports. The prescribing-information safety warnings are regulatory labeling, not efficacy evidence.
Source access and dates: Original reports, registry records and official safety sources available through the links above were checked November 9, 2026. Last literature search November 9, 2026.
Educational evidence summary, not individualized medical advice. Investigational or repurposed products should not replace established cancer treatment. Symptom, biomarker, laboratory or animal findings do not establish tumor control, recurrence prevention or longer survival.
